Filing Flows › ADC Therapeutics SA (ADCT) › R&D spending
ADC Therapeutics SA (ADCT) R&D spending by quarter
ADC Therapeutics SA's R&D spending was $17.4M in Q2 2026 (second quarter 2026), -13% from Q1 2026. Over the last 7 quarters it ranged from $17.4M (Q2 2026) to $30.1M (Q2 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $17.4M | -13% | -42% |
| Q1 2026 | $19.9M | +9% | -31% |
| Q4 2025 | $18.2M | -32% | -33% |
| Q3 2025 | $26.8M | -11% | — |
| Q2 2025 | $30.1M | +4% | — |
| Q1 2025 | $28.9M | +7% | — |
| Q4 2024 | $27.1M | — | — |
Q2 2026 at a glance
ADC Therapeutics SA, Q2 2026: revenue $19.2M (+2% year over year), operating margin -132.0%, net loss $16.6M, operating cash flow −$11.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is ADC Therapeutics SA's R&D spending?
ADC Therapeutics SA's R&D spending was $17.4M in Q2 2026 (second quarter 2026), -13% from Q1 2026.
How has ADC Therapeutics SA's R&D spending changed?
Over the last 7 quarters it ranged from $17.4M (Q2 2026) to $30.1M (Q2 2025).